[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-myelofibrosis-fibrotic-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-myelofibrosis-fibrotic-stage":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100434814","interest-of-calr-allele-burden-in-diagnosis-and-follow-up-of-patients-with-calr-mutated-myeloproliferative-syndromes-calrsuivi-100434814",false,"NCT04942080","Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","CALRSUIVI","Inclusion Criteria:\n\n* adults (age ≥18 years),\n* affiliated to the national social security system,\n* with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,\n* for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,\n* who signed the consent to participate in the study,\n* included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).\n\nExclusion Criteria:\n\n* patient with another active hematological disease or cancer at the time of diagnosis,\n* person subject to legal protection scheme or incapable of giving consent.","ALL","18 Years",{"count":19,"type":20},260,"ESTIMATED","INTERVENTIONAL",[23],"NA","Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.",[26,27,28,29],"Myeloproliferative Neoplasm","Essential Thrombocythemia","Primary Myelofibrosis, Prefibrotic Stage","Primary Myelofibrosis, Fibrotic Stage",[31,26,27,32,33],"CALR","Primary Myelofibrosis","Thrombocytosis","RECRUITING","2026-03-05",{"date":37,"type":38},"2026-03-06","ACTUAL",{"date":40,"type":38},"2021-10-28",{"date":42,"type":20},"2030-04-28",{"name":44,"class":45},"University Hospital, Angers","OTHER_GOV",10,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100507083","asian-myeloproliferative-neoplasm-mpn-registry-100507083","NCT05882773","Asian Myeloproliferative Neoplasm (MPN) Registry","Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.","Inclusion Criteria:\n\n1. Age ≥ 18 years old at the time of diagnosis of MPN.\n2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):\n\n   1. Polycythaemia vera\n   2. Essential thrombocythemia\n   3. Primary myelofibrosis, pre-fibrotic\u002Fearly stage\n   4. Primary myelofibrosis, overt fibrotic stage\n   5. Post-polycythaemia vera myelofibrosis\n   6. Post-essential thrombocythaemia myelofibrosis\n   7. MPN-unclassifiable\n3. All subjects need to provide informed consent.\n\nExclusion Criteria:\n\nA subject will not be eligible if he\u002Fshe meets any of the following criteria:\n\n1\\. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome\u002Fmyeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification",{"count":55,"type":20},1000,"10 Years","OBSERVATIONAL","This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.",[26,60,27,61,62,32,28,29],"Polycythemia Vera","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[64,65,66,67],"Myeloproliferative neoplasm","Epidemiology","Outcome","Prognostic factors","2023-05-21",{"date":70,"type":38},"2023-05-31",{"date":72,"type":20},"2023-05",{"date":74,"type":20},"2026-12",{"name":76,"class":77},"The University of Hong Kong","OTHER",1]